Tomaras Stylianos, Keyßer Gernot, Feist Eugen
Department of Rheumatology, HELIOS Clinic Vogelsang-Gommern, 39245 Vogelsang-Gommern, Germany.
Clinic for Internal Medicine II, Department of Internal Medicine, University Hospital Halle (Saale), Martin Luther University Halle-Wittenberg, 06120 Halle, Germany.
J Clin Med. 2022 May 20;11(10):2908. doi: 10.3390/jcm11102908.
Plant-derived nutraceuticals are proposed as new key instruments to represent a profound "back to basics" shift in medical treatment. Data accumulated over the past ten years suggest that curcumin, the major active compound of the turmeric plant, has anti-inflammatory properties. It has yet to be determined whether the anti-inflammatory profile of curcumin is potent enough to justify the application of this substance as a nutritional supplement for patients with rheumatic diseases. To address this question, the most relevant in vitro studies that investigate the mechanism of action of curcumin were reviewed in this article. In addition, a total of 18 animal and human trials were evaluated. The pleiotropic, anti-inflammatory and immunomodulatory effects of curcumin were observed in animal studies. In addition, human trials demonstrated promising findings. In these studies, curcumin was able to reduce the expression of proinflammatory cytokines, lower the level of the C-reactive protein and improve clinical parameters. A limiting factor of the application of curcumin is the inconsistent bioavailability of the substance. Therefore, new formulations have been developed to improve the pharmacodynamic profile of curcumin. The future acceptance of the substance is dependent on new controlled clinical trials with a standardised formulation of curcumin administered as well as standard of care.
植物源营养保健品被认为是实现医疗领域“回归基础”这一深刻转变的新关键手段。过去十年积累的数据表明，姜黄植物的主要活性成分姜黄素具有抗炎特性。姜黄素的抗炎特性是否强大到足以证明将该物质用作风湿病患者的营养补充剂，这一点尚待确定。为解决这个问题，本文综述了研究姜黄素作用机制的最相关体外研究。此外，还评估了总共18项动物和人体试验。在动物研究中观察到了姜黄素的多效性、抗炎和免疫调节作用。此外，人体试验也取得了有前景的结果。在这些研究中，姜黄素能够降低促炎细胞因子的表达，降低C反应蛋白水平并改善临床参数。姜黄素应用的一个限制因素是该物质的生物利用度不一致。因此，已开发出新的制剂来改善姜黄素的药效学特性。该物质未来能否被接受取决于采用标准化姜黄素制剂以及标准治疗方案的新对照临床试验。
